Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
May 08 2023 - 7:30AM
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage
immuno-oncology company focusing on developing next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications, today announced the
appointment of Monic Stuart, M.D., as its new Chief Medical
Officer. Dr. Stuart brings more than 20 years of experience as a
clinician-scientist and drug developer to Marker Therapeutics where
she will be responsible for advancing the development of
multi-tumor associated antigen (multiTAA)-specific T cell product
pipeline, including the ongoing MT-401 Phase 2 ARTEMIS clinical
study and Phase 1 clinical study of MT-601.
“As we undergo a strategic review of our
clinical programs, we are thrilled to add Monic to the leadership
team at Marker Therapeutics and look forward to benefitting from
her deep scientific, industry, and medical knowledge to drive our
multiTAA-specific T cell product pipeline across multiple high-need
cancer indications,” said Juan F. Vera, M.D., Chief Executive
Officer of Marker Therapeutics. “Given Marker’s prioritization of
the clinical program in acute myeloid leukemia (AML) and lymphoma,
bringing on a CMO who is a transplant physician and has extensive
experience in treating AML and lymphoma patients is a tremendous
advantage in establishing our clinical strategy. Dr. Stuart’s
impressive career both in industry and in the clinic as a treating
physician will be key to enabling Marker to identify the optimal
paths for advancing our programs targeting hematologic and solid
tumors.”
Dr. Stuart joins Marker Therapeutics as a
consultant after having most recently worked as interim Chief
Medical Officer, Head of Clinical Development or Clinical Advisor
for numerous biotechnology and pharmaceutical companies worldwide.
In this capacity, Dr. Stuart was responsible for leading each
company’s clinical strategy including clinical development plans,
Phase 1-3 study designs, and protocol development for a variety of
benign and malignant hematologic, solid tumor, and supportive care
indications. Dr. Stuart previously served as Vice President of
Clinical Development at Geron Corporation, where she spearheaded
efforts to develop a telomerase inhibitor in myeloid malignancies.
Before her role at Geron Corp., she worked at Genentech Inc. as a
Senior Medical Director in the Oncology Division. During her time
at Genentech, she served in leadership position for multiple early
and late-stage hematology/oncology programs.
Prior to Genentech, Dr. Stuart served as an
attending physician in the Division of Blood and Marrow
Transplantation at Stanford University, where she led trials in
myeloid malignancies. Dr. Stuart received her M.D and B.S. in
Biology from the University of North Carolina at Chapel Hill. She
completed her medical residency in internal medicine and
fellowships in hematology and bone marrow transplantation at
Stanford University. Dr. Stuart also holds a Master’s Degree from
the School of Public Health at Johns Hopkins University.
“Marker's unique T cell-based immunotherapies
have the potential to transform the treatment of cancer, and I am
excited to work with the team to advance the development of these
promising therapies,” said Dr. Stuart. “Importantly, the Company’s
MT-401 Phase 2 ARTEMIS clinical trial continues to advance with
recent data suggesting MT-401 manufactured with the improved T cell
manufacturing process would be well suited for AML patients. I am
intrigued by this potential as well as the opportunity to advance
our MT-601 program in non-Hodgkin lymphoma and pancreatic
cancer.”
About Marker Therapeutics,
Inc.Marker Therapeutics, Inc. is a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications. The cell
therapy technology Marker has is based on the selective expansion
of non-engineered, tumor-specific T cells that recognize tumor
associated antigens (i.e., tumor targets) and kill tumor cells
expressing those targets. This population of T cells is designed to
attack multiple tumor targets following infusion into patients and
to activate the patient’s immune system to produce broad spectrum
anti-tumor activity. Because Marker does not genetically engineer
its T cell therapies, we believe that our product candidates will
be easier and less expensive to manufacture, with reduced
toxicities, compared to current engineered CAR-T and TCR-based
approaches, and may provide patients with meaningful clinical
benefit. As a result, Marker believes its portfolio of T cell
therapies has a compelling product profile, as compared to current
gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email,
please visit: https://www.markertherapeutics.com/email-alerts.
Forward-Looking StatementsThis
release contains forward-looking statements for purposes of the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Statements in this news release concerning the
Company’s expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are “forward-looking statements.” Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research, development and regulatory
activities and expectations relating to our non-engineered
multi-tumor antigen specific T cell therapies; the effectiveness of
these programs or the possible range of application and potential
curative effects and safety in the treatment of diseases; and the
timing, conduct and success of our clinical trials of our product
candidates. Forward-looking statements are by their nature subject
to risks, uncertainties and other factors which could cause actual
results to differ materially from those stated in such statements.
Such risks, uncertainties and factors include, but are not limited
to the risks set forth in the Company’s most recent Form 10-K, 10-Q
and other SEC filings which are available through EDGAR
at WWW.SEC.GOV. The Company assumes no obligation to update
our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
ContactsTIBEREND
STRATEGIC ADVISORS, INC.InvestorsDaniel
Kontoh-Boateng(862) 213-1398dboateng@tiberend.com
MediaCasey McDonald(646)
577-8520cmcdonald@tiberend.com
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024